基于超分子“印迹模板”整合分析中药“十八反”配伍禁忌
|
摘要
"十八反"是传统中药配伍禁忌的重要内容,涉及中药临床用药安全有效的关键基础问题。在前期提出的中医药超分子"印迹模板"自主作用规律的基础上,以中药"十八反"反药对为对象,对其当前研究基础进行整合分析。首先分析总结了中药"十八反"的历史沿革,再运用超分子"印迹模板"解析中药配伍:中药配伍是将2种或2种以上中药有效成分群(客体分子)之间以非共价键进行结合,形成新的超分子体系,再与人体(主体分子)发生印迹作用,按"印迹模板"产生药效与毒效,宏观上表现出中药的配伍规律。基于此,再从超分子化学角度分别对"十八反"各组药对进行整合分析,最后提出了"十八反"的化学动力学、网络动力学、谱毒效动力学逐层推进的超分子毒与效整合研究方法,以期为"十八反"配伍禁忌机制研究提供思考和借鉴,为临床应用提供参考。
The "eighteen incompatible medicaments" is an important content of Chinese materia medica(CMM) compatibility contraindication, involving the key basic problem of safe and effective clinical use of CMM. Based on the rule of the automatic action of supramolecular "imprinting template" previously proposed, the current research basis of "eighteen incompatible medicaments" were integrated and analyzed. Firstly, the history of "eighteen incompatible medicaments" were summarized, then the theory of Chinese materia medica(CMM) compatibility was interpreted by supramolecular "imprinting template": the compatibility of CMM are that two or more than two kinds of CMM effective components group of molecules(object) are combined by non-covalent bonds, and the new formed supramolecular system and the human body(subject) are interacted with each other according to "imprinting template", and then the toxicity and efficacy were generated, while the compatibility law of CMM is displayed macroscopically. Based on this, three groups of "eighteen incompatible medicaments" were discussed from the perspective of supramolecular chemistry, and the supramolecular method integrating toxicity with efficacy was put forward, including"chemicalkinetics", "network kinetics" and "spectrum toxicity and efficacy kinetics" methods, thereby providing the ideas and reference for the research on the mechanism of "eighteen incompatible medicaments" and providing reference for clinical application.
The "eighteen incompatible medicaments" is an important content of Chinese materia medica(CMM) compatibility contraindication, involving the key basic problem of safe and effective clinical use of CMM. Based on the rule of the automatic action of supramolecular "imprinting template" previously proposed, the current research basis of "eighteen incompatible medicaments" were integrated and analyzed. Firstly, the history of "eighteen incompatible medicaments" were summarized, then the theory of Chinese materia medica(CMM) compatibility was interpreted by supramolecular "imprinting template": the compatibility of CMM are that two or more than two kinds of CMM effective components group of molecules(object) are combined by non-covalent bonds, and the new formed supramolecular system and the human body(subject) are interacted with each other according to "imprinting template", and then the toxicity and efficacy were generated, while the compatibility law of CMM is displayed macroscopically. Based on this, three groups of "eighteen incompatible medicaments" were discussed from the perspective of supramolecular chemistry, and the supramolecular method integrating toxicity with efficacy was put forward, including"chemicalkinetics", "network kinetics" and "spectrum toxicity and efficacy kinetics" methods, thereby providing the ideas and reference for the research on the mechanism of "eighteen incompatible medicaments" and providing reference for clinical application.
引文
[1]唐于平,沈娟,陶伟伟,等.中药配伍禁忌复杂毒效物质相互作用研究思路与方法[J].中国药理学与毒理学杂志,2015,29(6):954-959.
[2]欧丽娜,钟赣生,柳海艳,等.中药“十八反”的历史沿革、宜忌争论与思考建议[J].科技导报,2015,33(16):88-94.
[3]周晋,刘惠,刘文龙,等.基于超分子“印迹模板”分析的中药毒与效整合模式探讨[J].药学学报,2018,53(11):1808-1816.
[4]Lehn J M.Supramolecular chemistry:Where from?Where to?[J].Chem Soc Rev,2017,46(9):2378-2379.
[5]Mattia E,Otto S.Supramolecular systems chemistry[J].Nat Nanotechnol,2015,10(2):111-119.
[6]Busseron E,Ruff Y,Moulin E,et al.Supramolecular self-assemblies as functional nanomaterials[J].Nanoscale,2013,5(16):7098-7140.
[7]Sahoo D,Peterca M,Aqad E,et al.Hierarchical self-organization of perylene bisimides into supramolecular spheres and periodic arrays thereof[J].JAm Chem Soc,2016,138(44):14798-14807.
[8]Yang H,Yuan B,Zhang X,et al.Supramolecular chemistry at interfaces:host-guest interactions for fabricating multifunctional biointerfaces[J].Accounts Chem Res,2014,47(7):2106-2115.
[9]Kolesnichenko I V,Anslyn E V.Practical applications of supramolecular chemistry[J].Chem Soc Rev,2017,46(9):2385-2390.
[10]李惟.生物超分子体系[M].北京:化学工业出版社,现代生物技术与医药科技出版中心,2003.
[11]贺福元,周逸群,邓凯文,等.超分子化学对中医药理论的特殊影响[J].中国中药杂志,2014,39(8):1534-1543.
[12]Park S,Lee S Y,Park K M,et al.Supramolecular networking of macrocycles based on exo-coordination:From discrete to continuous frameworks[J].Accounts Chem Res,2011,45(3):391-403.
[13]周晋,刘惠,肖美凤,等.基于超分子“印迹模板”的中药成药性及制剂修饰研究策略[J].中草药,2018,49(18):6-12.
[14]刘惠,刘文龙,唐闻汉,等.基于超分子“印迹模板”理论探讨中药四性[J].中草药,2018,49(19):4473-4479.
[15]刘惠,贺红,朱志飞,等.金银花与山银花体外印迹等效性的研究[J].中草药,2019,50(4):829-835.
[16]肖美凤,张雨恬,杨岩涛,等.基于鱼腥草挥发性成分动态性的中药制剂“印迹模板”一致性分析[J].中国实验方剂学杂志,2019,25(14):150-155.
[17]贺福元,贺红,周逸群,等.中药注射剂超分子“印迹模板”特征对其(类)致敏性影响的探讨[J].中国中药杂志,2016,41(2):345-349.
[18]刘帅,李妍,李卫飞,等.乌头类中药毒性及现代毒理学研究进展[J].中草药,2016,47(22):4095-4102.
[19]王超,王宇光,梁乾德,等.UPLC/Q-TOFMS分析十八反乌头半夏配伍化学成分的变化[J].药学学报,2010,43(10):1301-1306.
[20]周思思,马增春,梁乾德,等.基于UPLC/Q-TOF-MS分析附子半夏配伍相反的物质基础[J].化学学报,2012,70(3):284-290.
[21]赵海峰,张蓉娟,张萌,等.附子、瓜蒌合煎薄层指纹图谱研究[J].陕西中医,2012,33(12):1666-1667.
[22]王超,王宇光,梁乾德,等.乌头与贝母配伍化学成分变化的UPLC/Q-TOFMS研究[J].化学学报,2011,69(16):1920-1928.
[23]刘文龙,宋凤瑞,刘志强,等.川乌与半夏,瓜蒌,贝母,白蔹,白芨配伍禁忌的化学研究[J].化学学报,2010,68(9):889-896.
[24]金科涛,石苏英,沈建幸,等.半夏、乌头合用对大鼠肝脏CYP450的调节作用[J].中华中医药学刊,2007,25(7):1358-1361.
[25]陈红,程再兴,吴锦俊,等.川乌配伍半夏对大鼠CYP3A的影响[J].中国实验方剂学杂志,2017,23(2):75-80.
[26]张琦.十八反“半蒌贝蔹芨攻乌”物质基础及毒性研究[D].长春:长春中医药大学,2010.
[27]马瑜红,李玲,阮耀,等.附子与瓜蒌配伍对大鼠心、肝、肾脏的毒性作用[J].中国老年学杂志,2011,31(22):4399-4401.
[28]刘萍,黄川锋,李玲,等.附子配伍贝母对大鼠心、肝、肾脏毒性的实验研究[J].时珍国医国药,2010,21(7):1801-1803.
[29]张寒,贾敏.白蔹,乌头合用对小鼠心、肝、肾功能及病理形态的影响[J].中国实验方剂学杂志,2012,18(20):283-285.
[30]金科涛,王宇光,石苏英,等.乌头、白及配伍存在基于CYP3A1/2的相互作用[J].中华中医药杂志,2007,22(9):598-602.
[31]孙萌,卢志强,庄朋伟,等.附子、白及反药组合对乙酸诱导大鼠胃溃疡的影响及其机制研究[J].现代药物与临床,2016,31(9):1319-1324.
[32]张玉龙,王梦月,杨静玉,等.炙甘草化学成分及药理作用研究进展[J].上海中医药大学学报,2015,29(3):99-102.
[33]曹琰.基于“十八反”的中药配伍禁忌理论基础研究-中药海藻与甘草配伍毒效表征与物质基础研究[D].南京:南京中医药大学,2014.
[34]王亮,张振秋,邓仕任,等.芫花甘草不同配伍比例的HPLC指纹图谱探讨[J].中国实验方剂学杂志,2015,21(2):80-82.
[35]王新敏.基于“十八反”的中药配伍禁忌理论基础研究-基于细胞色素P450酶系的“藻戟遂芫”与甘草相互作用研究[D].南京:南京中医药大学,2013.
[36]李怡文,钟赣生,柳海艳,等.基于均匀设计的海藻玉壶汤中海藻、甘草不同比例配伍对甲状腺肿大大鼠模型心、肾功能影响的实验研究[J].中华中医药学刊,2014,32(5):1011-1015.
[37]颜辉,王国基,陈坚.不同比例海藻与甘草配伍对大鼠的毒性研究[J].中国中药杂志,2007,32(16):1700-1703.
[38]夏成云,高月,周京国,等.大戟配伍甘草对大鼠肝功能及肝脏微粒体中CYP3A2的影响[J].中国中医急症,2006,15(9):1013-1015.
[39]黄文权,程相岭,肖鸿,等.甘草大戟同用对大鼠心肝肾功能及病理形态的影响[J].成都中医药大学学报,2003,26(1):37-39.
[40]代方国,罗仁,王宇光,等.甘遂配伍甘草对大鼠肝脏CYP3A2影响[J].第四军医大学学报,2005,26(10):951-953.
[41]王嘉琛,叶花,刘培,等.十八反药对甘草与甘遂配伍前后及其相应经方甘遂半夏汤对大鼠脏器及生化指标影响的研究[J].山西中医学院学报,2018,19(1):15-16.
[42]肖成荣,王宇光,代方国,等.甘草、芫花合用对大鼠肝脏细胞色素P450酶的影响[J].中国实验方剂学杂志,2006,24(12):48-50.
[43]代方国,罗仁,王宇光,等.甘遂配伍甘草对大鼠肝脏CYP2E1表达及活性的影响[J].第三军医大学学报,2005,27(8):742-744.
[44]徐芝秀,石苏英,金科涛,等.甘草与海藻、大戟、芫花配伍对大鼠肝脏CYP2E1酶活性及m RNA表达的影响[J].中国药物与临床,2007,7(7):493-495.
[45]汤建,李慧梁,黄海强,等.藜芦属植物化学成分的研究近况[J].药学进展,2006,30(5):206-212.
[46]荆敏琪,张会平,赵旻,等.基于HPLC法研究苦参藜芦反药对配伍禁忌机制[J].沈阳药科大学学报,2018,35(8):632-638.
[47]王宇光,王超,梁乾德,等.十八反中藜芦与人参配伍化学成分变化的UPLC/Q-TOFMS研究[J].中国科学:生命科学,2011,41(10):925-932.
[48]孟宪生,康廷国,叶挺祥,等.中药细辛与藜芦配伍化学成分变化的UPLC/Q-TOF-MS研究[J].中华中医药学刊,2010,28(4):754-759.
[49]王宇光,高月,柴彪新,等.人参、藜芦合用对大鼠肝P450酶活性及m RNA表达的调控作用[J].中国中药杂志,2004,29(4):366-370.
[50]王辰允,叶旋,王宇光,等.人参与藜芦合用对CYP1A酶活性的影响[J].解放军药学学报,2010,26(2):104-106.
[51]孟浩,王宇光,肖成荣,等.藜芦与人参配伍连续8周给药对大鼠心脏毒性的影响[J].中华中医药杂志,2014,29(3):840-843.
[52]边向阳,徐彭,金科涛.中药藜芦及其与玄参合用对大鼠肝脏CYP3A1/2酶活性的影响[J].江西医药,2008,43(11):1155-1157.
[53]李飞.基于药物相互作用的藜芦配伍丹参毒性研究[D].长沙:中南大学,2013.
[54]姚凝.丹参与藜芦配伍对小鼠肝脏及肾脏的影响[J].中药材,2014,37(3):482-484.
[55]朱冠秀.南、北沙参与藜芦配伍增毒相互作用研究[D].长沙:中南大学,2013.
[56]周建明,王宇光,陈志武,等.苦参、藜芦合用对大鼠肝P450酶活性及m RNA表达的调控作用[J].中国中药杂志,2010,35(14):1845-1849.
[57]林洁,林晖,黄鹏,等.Cocktail探针法测定细辛与藜芦配伍对大鼠肝细胞色素P450亚酶活性的影响[J].中药材,2014,37(7):1251-1254.
[58]林洁,林晖,黄鹏,等.Cocktail探针法测定三种不同来源细辛与藜芦配伍用药对大鼠肝细胞色素P450亚酶活性的影响[J].中药材,2014,37(10):1841-1844.
[59]姚凝.赤芍与藜芦配伍对小鼠肝脏及肾脏损伤的影响[J].中国中医药信息杂志,2014,21(5):46-49.
[60]zur Wiesch P A,Clarelli F,Cohen T.Using chemical reaction kinetics to predict optimal antibiotic treatment strategies[J].PLoS Comput Biol,2017,13(1):e1005321.
[61]贺福元,周宏灏,罗杰英.多成分药物代谢网络动力学数学模型建立及参数分析[J].中国临床药理学与治疗学,2007,12(12):1321-1331.
[2]欧丽娜,钟赣生,柳海艳,等.中药“十八反”的历史沿革、宜忌争论与思考建议[J].科技导报,2015,33(16):88-94.
[3]周晋,刘惠,刘文龙,等.基于超分子“印迹模板”分析的中药毒与效整合模式探讨[J].药学学报,2018,53(11):1808-1816.
[4]Lehn J M.Supramolecular chemistry:Where from?Where to?[J].Chem Soc Rev,2017,46(9):2378-2379.
[5]Mattia E,Otto S.Supramolecular systems chemistry[J].Nat Nanotechnol,2015,10(2):111-119.
[6]Busseron E,Ruff Y,Moulin E,et al.Supramolecular self-assemblies as functional nanomaterials[J].Nanoscale,2013,5(16):7098-7140.
[7]Sahoo D,Peterca M,Aqad E,et al.Hierarchical self-organization of perylene bisimides into supramolecular spheres and periodic arrays thereof[J].JAm Chem Soc,2016,138(44):14798-14807.
[8]Yang H,Yuan B,Zhang X,et al.Supramolecular chemistry at interfaces:host-guest interactions for fabricating multifunctional biointerfaces[J].Accounts Chem Res,2014,47(7):2106-2115.
[9]Kolesnichenko I V,Anslyn E V.Practical applications of supramolecular chemistry[J].Chem Soc Rev,2017,46(9):2385-2390.
[10]李惟.生物超分子体系[M].北京:化学工业出版社,现代生物技术与医药科技出版中心,2003.
[11]贺福元,周逸群,邓凯文,等.超分子化学对中医药理论的特殊影响[J].中国中药杂志,2014,39(8):1534-1543.
[12]Park S,Lee S Y,Park K M,et al.Supramolecular networking of macrocycles based on exo-coordination:From discrete to continuous frameworks[J].Accounts Chem Res,2011,45(3):391-403.
[13]周晋,刘惠,肖美凤,等.基于超分子“印迹模板”的中药成药性及制剂修饰研究策略[J].中草药,2018,49(18):6-12.
[14]刘惠,刘文龙,唐闻汉,等.基于超分子“印迹模板”理论探讨中药四性[J].中草药,2018,49(19):4473-4479.
[15]刘惠,贺红,朱志飞,等.金银花与山银花体外印迹等效性的研究[J].中草药,2019,50(4):829-835.
[16]肖美凤,张雨恬,杨岩涛,等.基于鱼腥草挥发性成分动态性的中药制剂“印迹模板”一致性分析[J].中国实验方剂学杂志,2019,25(14):150-155.
[17]贺福元,贺红,周逸群,等.中药注射剂超分子“印迹模板”特征对其(类)致敏性影响的探讨[J].中国中药杂志,2016,41(2):345-349.
[18]刘帅,李妍,李卫飞,等.乌头类中药毒性及现代毒理学研究进展[J].中草药,2016,47(22):4095-4102.
[19]王超,王宇光,梁乾德,等.UPLC/Q-TOFMS分析十八反乌头半夏配伍化学成分的变化[J].药学学报,2010,43(10):1301-1306.
[20]周思思,马增春,梁乾德,等.基于UPLC/Q-TOF-MS分析附子半夏配伍相反的物质基础[J].化学学报,2012,70(3):284-290.
[21]赵海峰,张蓉娟,张萌,等.附子、瓜蒌合煎薄层指纹图谱研究[J].陕西中医,2012,33(12):1666-1667.
[22]王超,王宇光,梁乾德,等.乌头与贝母配伍化学成分变化的UPLC/Q-TOFMS研究[J].化学学报,2011,69(16):1920-1928.
[23]刘文龙,宋凤瑞,刘志强,等.川乌与半夏,瓜蒌,贝母,白蔹,白芨配伍禁忌的化学研究[J].化学学报,2010,68(9):889-896.
[24]金科涛,石苏英,沈建幸,等.半夏、乌头合用对大鼠肝脏CYP450的调节作用[J].中华中医药学刊,2007,25(7):1358-1361.
[25]陈红,程再兴,吴锦俊,等.川乌配伍半夏对大鼠CYP3A的影响[J].中国实验方剂学杂志,2017,23(2):75-80.
[26]张琦.十八反“半蒌贝蔹芨攻乌”物质基础及毒性研究[D].长春:长春中医药大学,2010.
[27]马瑜红,李玲,阮耀,等.附子与瓜蒌配伍对大鼠心、肝、肾脏的毒性作用[J].中国老年学杂志,2011,31(22):4399-4401.
[28]刘萍,黄川锋,李玲,等.附子配伍贝母对大鼠心、肝、肾脏毒性的实验研究[J].时珍国医国药,2010,21(7):1801-1803.
[29]张寒,贾敏.白蔹,乌头合用对小鼠心、肝、肾功能及病理形态的影响[J].中国实验方剂学杂志,2012,18(20):283-285.
[30]金科涛,王宇光,石苏英,等.乌头、白及配伍存在基于CYP3A1/2的相互作用[J].中华中医药杂志,2007,22(9):598-602.
[31]孙萌,卢志强,庄朋伟,等.附子、白及反药组合对乙酸诱导大鼠胃溃疡的影响及其机制研究[J].现代药物与临床,2016,31(9):1319-1324.
[32]张玉龙,王梦月,杨静玉,等.炙甘草化学成分及药理作用研究进展[J].上海中医药大学学报,2015,29(3):99-102.
[33]曹琰.基于“十八反”的中药配伍禁忌理论基础研究-中药海藻与甘草配伍毒效表征与物质基础研究[D].南京:南京中医药大学,2014.
[34]王亮,张振秋,邓仕任,等.芫花甘草不同配伍比例的HPLC指纹图谱探讨[J].中国实验方剂学杂志,2015,21(2):80-82.
[35]王新敏.基于“十八反”的中药配伍禁忌理论基础研究-基于细胞色素P450酶系的“藻戟遂芫”与甘草相互作用研究[D].南京:南京中医药大学,2013.
[36]李怡文,钟赣生,柳海艳,等.基于均匀设计的海藻玉壶汤中海藻、甘草不同比例配伍对甲状腺肿大大鼠模型心、肾功能影响的实验研究[J].中华中医药学刊,2014,32(5):1011-1015.
[37]颜辉,王国基,陈坚.不同比例海藻与甘草配伍对大鼠的毒性研究[J].中国中药杂志,2007,32(16):1700-1703.
[38]夏成云,高月,周京国,等.大戟配伍甘草对大鼠肝功能及肝脏微粒体中CYP3A2的影响[J].中国中医急症,2006,15(9):1013-1015.
[39]黄文权,程相岭,肖鸿,等.甘草大戟同用对大鼠心肝肾功能及病理形态的影响[J].成都中医药大学学报,2003,26(1):37-39.
[40]代方国,罗仁,王宇光,等.甘遂配伍甘草对大鼠肝脏CYP3A2影响[J].第四军医大学学报,2005,26(10):951-953.
[41]王嘉琛,叶花,刘培,等.十八反药对甘草与甘遂配伍前后及其相应经方甘遂半夏汤对大鼠脏器及生化指标影响的研究[J].山西中医学院学报,2018,19(1):15-16.
[42]肖成荣,王宇光,代方国,等.甘草、芫花合用对大鼠肝脏细胞色素P450酶的影响[J].中国实验方剂学杂志,2006,24(12):48-50.
[43]代方国,罗仁,王宇光,等.甘遂配伍甘草对大鼠肝脏CYP2E1表达及活性的影响[J].第三军医大学学报,2005,27(8):742-744.
[44]徐芝秀,石苏英,金科涛,等.甘草与海藻、大戟、芫花配伍对大鼠肝脏CYP2E1酶活性及m RNA表达的影响[J].中国药物与临床,2007,7(7):493-495.
[45]汤建,李慧梁,黄海强,等.藜芦属植物化学成分的研究近况[J].药学进展,2006,30(5):206-212.
[46]荆敏琪,张会平,赵旻,等.基于HPLC法研究苦参藜芦反药对配伍禁忌机制[J].沈阳药科大学学报,2018,35(8):632-638.
[47]王宇光,王超,梁乾德,等.十八反中藜芦与人参配伍化学成分变化的UPLC/Q-TOFMS研究[J].中国科学:生命科学,2011,41(10):925-932.
[48]孟宪生,康廷国,叶挺祥,等.中药细辛与藜芦配伍化学成分变化的UPLC/Q-TOF-MS研究[J].中华中医药学刊,2010,28(4):754-759.
[49]王宇光,高月,柴彪新,等.人参、藜芦合用对大鼠肝P450酶活性及m RNA表达的调控作用[J].中国中药杂志,2004,29(4):366-370.
[50]王辰允,叶旋,王宇光,等.人参与藜芦合用对CYP1A酶活性的影响[J].解放军药学学报,2010,26(2):104-106.
[51]孟浩,王宇光,肖成荣,等.藜芦与人参配伍连续8周给药对大鼠心脏毒性的影响[J].中华中医药杂志,2014,29(3):840-843.
[52]边向阳,徐彭,金科涛.中药藜芦及其与玄参合用对大鼠肝脏CYP3A1/2酶活性的影响[J].江西医药,2008,43(11):1155-1157.
[53]李飞.基于药物相互作用的藜芦配伍丹参毒性研究[D].长沙:中南大学,2013.
[54]姚凝.丹参与藜芦配伍对小鼠肝脏及肾脏的影响[J].中药材,2014,37(3):482-484.
[55]朱冠秀.南、北沙参与藜芦配伍增毒相互作用研究[D].长沙:中南大学,2013.
[56]周建明,王宇光,陈志武,等.苦参、藜芦合用对大鼠肝P450酶活性及m RNA表达的调控作用[J].中国中药杂志,2010,35(14):1845-1849.
[57]林洁,林晖,黄鹏,等.Cocktail探针法测定细辛与藜芦配伍对大鼠肝细胞色素P450亚酶活性的影响[J].中药材,2014,37(7):1251-1254.
[58]林洁,林晖,黄鹏,等.Cocktail探针法测定三种不同来源细辛与藜芦配伍用药对大鼠肝细胞色素P450亚酶活性的影响[J].中药材,2014,37(10):1841-1844.
[59]姚凝.赤芍与藜芦配伍对小鼠肝脏及肾脏损伤的影响[J].中国中医药信息杂志,2014,21(5):46-49.
[60]zur Wiesch P A,Clarelli F,Cohen T.Using chemical reaction kinetics to predict optimal antibiotic treatment strategies[J].PLoS Comput Biol,2017,13(1):e1005321.
[61]贺福元,周宏灏,罗杰英.多成分药物代谢网络动力学数学模型建立及参数分析[J].中国临床药理学与治疗学,2007,12(12):1321-1331.